Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS-RAF-MEK pathway mutations. METHODS We did a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study at the Royal Marsden National Health Service Foundation Trust (London, UK). Patients were eligible for the study if they were aged 18 years or older, had cancers that were refractory to conventional treatment or for which no conventional therapy existed, and if they had a WHO performance status score of 0 or 1. For the dose-escalation phase, eligible patients had histologically or cytologically confirmed advanced or metastatic solid tumours. For the basket dose-expansion phase, eligible patients had advanced or metastatic solid tumours or multiple myeloma harbouring RAS-RAF-MEK pathway mutations. During the dose-escalation phase, we evaluated three intermittent oral schedules (28-day cycles) in patients with solid tumours: (1) 4·0 mg or 3·2 mg CH5126766 three times per week; (2) 4·0 mg CH5126766 twice per week; and (3) toxicity-guided dose interruption schedule, in which treatment at the recommended phase 2 dose (4·0 mg C…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A phase I trial demonstrated that 30% of patients with KRASmutated NSCLC treated with avutometinib had an objective response; all these patients had a low frequency of adverse events that lasted longer than 6 months [17].”
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
McCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Research works printed but not linked: 1
- Canon, 2019, The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity, Nature, 575, 217, 10.1038/s41586-019-1694-1 · DOI · Paper page
Cited by
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
“Guo and colleagues (56) reported a phase Ib study of the MEK inhibitor VS-6766 (previously known as CH5126766 or RO5126766), which showed promising antitumor activity across a spectrum of KRAS-mutant tumors, including KRASG12V mutation-positive NSCLC.”
BackgroundEmerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 226
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Metadata
- Authors
- Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., King, J., Parmar, M., Turner, A. J., Carreira, S., Riisnaes, R., Finneran, L., Hall, E., Ishikawa, Y., Nakai, K., Tunariu, N., Basu, B., Kaiser, M., Lopez, J. S., Minchom, A., de Bono, J. S., & Banerji, U.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- University of Cambridge (GB)
- Corresponding author
- Banerji, Udai
- ORCID
- Guo, Christina
- Chénard-Poirier, Maxime
- Roda, Desamparados
- Sriskandarajah, Priya
- Xu, Wen
- Scaranti, Mariana
- Constantinidou, Anastasia
- Parmar, Mona
- Turner, Alison J
- Carreira, Suzanne
- Riisnaes, Ruth
- Finneran, Laura
- Hall, Emma
- Ishikawa, Yuji
- Tunariu, Nina
- Basu, Bristi
- Kaiser, Martin
- Lopez, Juanita Suzanne
- Minchom, Anna
- Banerji, Udai
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 21
- Issue
- 11
- Pages
- 1478-1488
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3097863157
- Cited by
- 78
- References
- 30
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 14 · 2023: 8 · 2022: 15 · 2021: 14 · 2020: 1
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-02-01)
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
- Apollo
- Funders
- Chugai Pharmaceutical
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health Research
- Cancer Research UK
- Institute of Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- RAF/MEK inhibitors, intermittent dosing, multiple myeloma, solid tumors, dose escalation, dose expansion, safety and toxicity, antitumour activity, recommended phase 2 dose, refractory cancer, oral anticancer drugs
- MeSH terms
- Administration, Oral, Adult, Aged, Coumarins, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors, raf Kinases, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30464-2
- The paper
- Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., King, J., Parmar, M., Turner, A. J., Carreira, S., Riisnaes, R., Finneran, L., Hall, E., Ishikawa, Y., Nakai, K., . . . Banerji, U. (2020). Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30464-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.